June 4, 2024
Genetic Signatures (ASX:GSS) – Allison Rossiter appointed as CEO
Genetic Signatures welcomes Allison Rossiter, as the incoming CEO.
May 31, 2024
Genetic Signatures (ASX:GSS) – Trading Halt 31st May 2024
Commencement of normal trading on Thursday, 6 June 2024.
May 27, 2024
Genetic Signatures (ASX:GSS) – Decision to Cease Development of US Respiratory Product
May 3, 2024
Genetic Signatures (ASX:GSS) – Application for quotation of securities
April 30, 2024
Genetic Signatures (ASX:GSS) – Leadership Transition at Genetic Signatures
Dr. John Melki has stepped down from his role as CEO of the Company and from the Board of Directors.
“His scientific and executive leadership have been pivotal in enabling the Company to successfully transition from a research and development company to a commercial organisation. We sincerely thank Dr. Melki for this and wish him the very best in his future endeavours.” said Dr. Nick Samaras, Chairman.
We thank John for his leadership, dedication to Genetic Signatures’ team and investors, and for his genuine passion for improving global health.
